These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 21127701)

  • 1. Low high-density lipoprotein cholesterol: current status and future strategies for management.
    Singh V; Sharma R; Kumar A; Deedwania P
    Vasc Health Risk Manag; 2010 Oct; 6():979-96. PubMed ID: 21127701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH).
    AIM-HIGH Investigators
    Am Heart J; 2011 Mar; 161(3):471-477.e2. PubMed ID: 21392600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
    Kones R
    Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.
    Chrysant SG; Ibrahim M
    J Clin Hypertens (Greenwich); 2006 Jul; 8(7):493-9; quiz 500-1. PubMed ID: 16849903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management.
    Boden WE
    Curr Opin Cardiol; 2003 Jul; 18(4):278-85. PubMed ID: 12858126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials.
    Sacks FM
    Am J Cardiol; 2001 Dec; 88(12A):14N-18N. PubMed ID: 11788125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels.
    Hausenloy DJ; Yellon DM
    Curr Opin Cardiol; 2009 Sep; 24(5):473-82. PubMed ID: 19574922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of low HDL-cholesterol levels in the reduction of cardiovascular risk].
    Stokić E; Marinkov J
    Med Pregl; 2007; 60(3-4):145-50. PubMed ID: 17853726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.
    Sharma RK; Singh VN; Reddy HK
    Vasc Health Risk Manag; 2009; 5():793-9. PubMed ID: 19812691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic role of niacin in dyslipidemia management.
    Boden WE; Sidhu MS; Toth PP
    J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
    ; Boden WE; Probstfield JL; Anderson T; Chaitman BR; Desvignes-Nickens P; Koprowicz K; McBride R; Teo K; Weintraub W
    N Engl J Med; 2011 Dec; 365(24):2255-67. PubMed ID: 22085343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Postgrad Med J; 2008 Nov; 84(997):590-8. PubMed ID: 19103817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New trends in lipidology: the increasing role of HDL-cholesterol].
    Paragh G; Harangi M; László M
    Orv Hetil; 2008 Jul; 149(30):1395-404. PubMed ID: 18621598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.